Researchers in the United Kingdom have found that a brief course of immunotherapy before surgery dramatically improves survival in patients with a specific type of colorectal cancer. The trial involved pembrolizumab, a drug that unleashes the immune system to attack cancer cells, administered for nine weeks before surgery. Nearly three years after treatment, patients remained cancer-free, a result that outperforms the conventional approach of operating first and then administering months of chemotherapy afterward.
This discovery centers on mismatch repair deficient colorectal cancers, a subset of tumors that carry genetic mutations affecting DNA repair mechanisms. These cancers respond exceptionally well to immunotherapy because their high mutation burden makes them more visible to immune cells. The nine-week neoadjuvant pembrolizumab regimen leverages this biology before surgery removes the tumor, essentially priming the immune system to recognize and eliminate remaining cancer cells.
The implications are substantial. Standard treatment typically subjects patients to toxic chemotherapy for extended periods after surgery, with significant side effects including nausea, fatigue, and organ damage. This new approach compresses treatment into a shorter window and replaces chemotherapy with immunotherapy for this patient population, potentially improving quality of life while delivering superior outcomes.
However, limitations exist. The results apply specifically to mismatch repair deficient tumors, which represent only about 3 to 5 percent of colorectal cancers. Patients with other colorectal cancer subtypes will require different treatment strategies. Additionally, the trial period of nearly three years, while encouraging, represents relatively early follow-up data. Longer observation periods will reveal whether these cancer-free survival gains persist over five, ten, and twenty-year timeframes, which doctors typically use to assess cure rates.
Pembrolizumab already holds FDA approval for various cancer types, but this application represents a novel use in the neoadjuv